Advertisement

Diabetologia

, Volume 20, Issue 1, pp 45–46 | Cite as

Buformin concentrations in a case of fatal lactic acidosis

  • L. F. Verdonck
  • B. Sangster
  • A. N. P. van Heijst
  • G. de Groot
  • R. A. A. Maes
Originals

Summary

A fatal case of lactic acidosis in a 84 year old diabetic woman taking buformin is reported. Buformin concentrations in serum, other body fluids and tissues were measured by gas chromatography. Serum buformin concentration at admission was 5.5 mg/1. Postmortem concentrations were: in serum 3.2mg/l; in lung 2.8mg/kg wet weight; in heart 3.0mg/kg; in pericardial fluid 3.5 mg/1; in liver 5.2 mg/kg; in bile 6.3 mg/1; and in kidney 98 mg/kg.

Key words

Lactic acidosis plasma buformin concentration tissue buformin concentration biguanides 

References

  1. 1.
    Lintz W, Berger W, Aenishaenslin W, Kutova V, Baerlocher Ch, Kapp JP, Beckmann R (1974) Butylbiguanide concentration in plasma, liver, and intestine after intravenous and oral administration to man. Eur J Clin Pharmacol 7: 433–448PubMedCrossRefGoogle Scholar
  2. 2.
    Berger W, Mehnert-Aner S, Mülly K, Heierli Ch, Ritz R (1976) 10 Fälle von Lactatazidose unter Biguanidtherapie (Buformin und Phenformin). Schweiz Med Wochenschr 106: 1830–1834PubMedGoogle Scholar
  3. 3.
    Althoff PH, Fassbinder W, Neubauer M, Koch KM, Schöffling K (1978) Hämodialyse bei der Behandlung der biguanidinduzierten Lactacidose. Dtsch Med Wochenschr 103: 61–68PubMedCrossRefGoogle Scholar
  4. 4.
    Irsigler K, Kritz H, Regal H, Foltin E (1978) Risiko zur Laktazidose? Wien Klin Wochenschr 90: 332–337PubMedGoogle Scholar
  5. 5.
    Grpot G de, Maes RAA, Sangster B, Heijst ANP van, Verdonck LF (1980) A specific method for the analysis of buformin in pre- and postmortem human material. Proceedings of the European Meeting of the International Association of Forensic Toxicologists, Glasgow, August 1979. Croom Helm, London, p 165–172Google Scholar
  6. 6.
    Alberti KGMM, Nattrass M (1977) Lactic acidosis: Lancet II: 25–29CrossRefGoogle Scholar
  7. 7.
    Ng ML, Levy MN, Zieske HA (1967) Effects of changes of pH and carbon dioxide tension on left ventricular performance. Am J Physiol 213: 115–120PubMedGoogle Scholar
  8. 8.
    Wildenthal K, Mierzwiak DS, Myers RW, Mitchell JH (1968) Effects of acute lactic acidosis on left ventricular performance. Am J Physiol 214: 1352–1359PubMedGoogle Scholar
  9. 9.
    Zähringer J, Cyran J, Lüderitz B (1978) Laktazidose bei Biguanidtherapie: Diagnostik und Therapie. Schweiz Med Wochenschr 108: 1838–1846PubMedGoogle Scholar
  10. 10.
    Bottermann P, Schweigart U, Ermler R (1976) Untersuchungen zum Wirkungsmechanismus von Buformin mit Hilfe tritiierter Glucose bei stoffwechselgesunden Personen. Med Klin 71: 1423–1428PubMedGoogle Scholar
  11. 11.
    Deppermann D, Heidland A, Ritz E, Hört W (1978) Lactat- Azidose. Eine mögliche Komplikation der Buformin-Therapie. Klin Wochenschr 56: 843–853PubMedCrossRefGoogle Scholar
  12. 12.
    Luft D, Schmülling RM, Eggstein M (1978) Lactic acidosis in biguanide-treated diabetics. Diabetologia 14: 75–87PubMedCrossRefGoogle Scholar
  13. 13.
    Beckmann R, Lintz W, Schmidt-Böthelt E (1971) Evaluation of a sustained release from of the oral antidiabetic butylbi- guanide (Silubin®-Retard). Eur J Clin Pharmacol 3: 221–228PubMedCrossRefGoogle Scholar
  14. 14.
    Losert W, Kolb K-H, Bitterling G (1972) Verteilung von 1- Butyl-biguanid-14C im Organismus von Ratten und Meer- schweinen. Arzneim Forsch 22: 937–946Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • L. F. Verdonck
    • 1
  • B. Sangster
    • 2
    • 3
  • A. N. P. van Heijst
    • 2
    • 3
  • G. de Groot
    • 4
  • R. A. A. Maes
    • 4
  1. 1.Departments of Internal MedicineUniversity HospitalUtrecht
  2. 2.Departments of Reanimation and Clinical ToxicologyUniversity HospitalUtrecht
  3. 3.National Poison Control CentreNational Institute of Public HealthBilthoven
  4. 4.Centre for Human ToxicologyState UniversityUtrechtNetherlands

Personalised recommendations